Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis

IntroductionCurrently, first-line immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) inhibitors, are utilized as monotherapy in advanced non-small cell lung cancer (NSCLC) patients with high programmed death ligand-1 (PD-L1) expression (≧50%). Pre-treatment or post...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Takashi Shimizu, Eisuke Inoue, Ryotaro Ohkuma, Shinichi Kobayashi, Takuya Tsunoda, Satoshi Wada
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2023-11-01
Schriftenreihe:	Frontiers in Immunology
Schlagworte:	soluble PD-L1 advanced non-small cell lung cancer PD-1 inhibitors individual patient data meta-analysis biomarker
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1308381/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!